Delabelling beta-lactam allergy.
| Autor: | Molina-Molina GJ; Allergy Department, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain., Garnica Velandia DR; Allergology Department, Hospital Universitari Santa Maria, Lleida, Spain.; Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRB Lleida), Lleida, Spain., Andrés-López B; Allergy Department, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain., Perales C; Allergology Section, Hospital de Tortosa Verge de La Cinta, Institut D'Investigació Sanitaria Pere I Virgili, Tortosa, Spain., Marin-Asensio L; Allergology Section, Hospital de Tortosa Verge de La Cinta, Institut D'Investigació Sanitaria Pere I Virgili, Tortosa, Spain., Jurgens Y; Allergy Section, University Hospital Germans Trias I Pujol, Badalona, Spain., Esteso O; Allergy Section, Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain., Escobar C; Allergy Department, Hospital Universitari Dr. Josep Trueta, Girona, Spain., Vidal X; Clinical Pharmacology Service, Hospital Universitari Vall D'Hebron, Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain., Vendrell L; Clinical Pharmacology Service, Hospital Universitari Vall D'Hebron, Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.; Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain., Gómez-Ganda L; Pharmacy Department, Hospital Universitari Vall D'Hebron, Barcelona, Spain., Rodríguez D; Clinical Pharmacology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain., Montané E; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.; Clinical Pharmacology Service, University Hospital Germans Trias I Pujol, Badalona, Spain., Cardona V; Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain.; Department of Allergy, Hospital Universitari Vall D'Hebron, Barcelona, Spain., Agustí A; Clinical Pharmacology Service, Hospital Universitari Vall D'Hebron, Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in pharmacology [Front Pharmacol] 2024 Jun 27; Vol. 15, pp. 1423719. Date of Electronic Publication: 2024 Jun 27 (Print Publication: 2024). |
| DOI: | 10.3389/fphar.2024.1423719 |
| Abstrakt: | Background: Hypersensitivity to beta-lactam (BL) antibiotics is one of the most frequent reported drug allergies. In our population, it is common to find labels of BL allergy in electronic medical records (EMRs) that have not been assessed. The objective of our study was to detect patients with beta-lactam allergy labels in their EMRs and to assess how many of them are false after a correct diagnostic evaluation. Methods: A multicentre prospective study was performed with patients labelled as allergic to BLs in their EMRs in the previous 5 years. Demographical and clinical data, as well as variables regarding the BL allergy label and the characteristics of the index reaction from clinical history and EMRs, were recorded. Then, diagnostic assessments including clinical history, skin tests (STs), and drug provocation tests (DPTs) were conducted in order to confirm or exclude the diagnosis of BL allergy. Results: A total of 249 patients completed the study, of which 160 (64.3%) were women with a median age of 57 years (interquartile range [IQR], 45-68). The most frequent BL allergy labels detected were for penicillin (124), amoxicillin/clavulanic acid (61), and amoxicillin (54). Of the 204 patients who underwent STs, 20.1% were positive. DPTs were performed in 224 patients, showing good tolerance in 87.1% of cases. After the allergy diagnosis work-up, 186 patients (74.7%) were diagnosed as non-allergic to BL antibiotics. Conclusion: In our study population, the number of patients labelled as allergic to BLs in their EMRs was similar to that in previously published studies, with proportions near to 75%-80% being falsely labelled as allergic to BLs. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Molina-Molina, Garnica Velandia, Andrés-López, Perales, Marin-Asensio, Jurgens, Esteso, Escobar, Vidal, Vendrell, Gómez-Ganda, Rodríguez, Montané, Cardona and Agustí.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|